310 related articles for article (PubMed ID: 9086008)
1. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies.
Watanabe T; Naito M; Kokubu N; Tsuruo T
J Natl Cancer Inst; 1997 Apr; 89(7):512-8. PubMed ID: 9086008
[TBL] [Abstract][Full Text] [Related]
2. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.
Naito M; Tsuge H; Kuroko C; Koyama T; Tomida A; Tatsuta T; Heike Y; Tsuruo T
J Natl Cancer Inst; 1993 Feb; 85(4):311-6. PubMed ID: 7678867
[TBL] [Abstract][Full Text] [Related]
4. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Uchiyama-Kokubu N; Watanabe T; Cohen D
Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
[TBL] [Abstract][Full Text] [Related]
5. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.
Watanabe T; Naito M; Oh-hara T; Itoh Y; Cohen D; Tsuruo T
Jpn J Cancer Res; 1996 Feb; 87(2):184-93. PubMed ID: 8609068
[TBL] [Abstract][Full Text] [Related]
6. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.
Uchiyama-Kokubu N; Watanabe T
Anticancer Drugs; 2001 Oct; 12(9):769-79. PubMed ID: 11593059
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
9. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models.
Watanabe T; Nakayama Y; Naito M; Oh-hara T; Itoh Y; Tsuruo T
Anticancer Drugs; 1996 Nov; 7(8):825-32. PubMed ID: 8991185
[TBL] [Abstract][Full Text] [Related]
10. [Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16, and their synergistic modulation of multidrug resistance].
Naito M; Tsuruo T
Gan To Kagaku Ryoho; 1994 Feb; 21(3):395-402. PubMed ID: 7906507
[TBL] [Abstract][Full Text] [Related]
11. [Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma].
Okano M; Kawamoto S; Nezasa S; Tamaki M; Ehara H; Yamada S; Deguchi T; Kawada Y
Nihon Hinyokika Gakkai Zasshi; 1996 Aug; 87(8):1041-7. PubMed ID: 8831211
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16.
Naito M; Tsuge H; Kuroko C; Tomida A; Tsuruo T
Jpn J Cancer Res; 1993 May; 84(5):489-92. PubMed ID: 8100562
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody.
Scott AM; Rosa E; Mehta BM; Divgi CR; Finn RD; Biedler JL; Tsuruo T; Kalaigian H; Larson SM
Nucl Med Biol; 1995 May; 22(4):497-504. PubMed ID: 7550027
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of multidrug resistant tumors and chemotherapeutic approaches against the resistant tumors].
Tsuruo T
Yakugaku Zasshi; 1997 Aug; 117(8):455-67. PubMed ID: 9306724
[TBL] [Abstract][Full Text] [Related]
15. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
16. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of KW-2170, a novel pyrazoloacridone derivative.
Ashizawa T; Shimizu M; Gomi K; Okabe M
Anticancer Drugs; 1998 Mar; 9(3):263-71. PubMed ID: 9625437
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers.
Pilarski LM; Yatscoff RW; Murphy GF; Belch AR
Leukemia; 1998 Apr; 12(4):505-9. PubMed ID: 9557608
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.
Watanabe T; Tsuge H; Oh-Hara T; Naito M; Tsuruo T
Acta Oncol; 1995; 34(2):235-41. PubMed ID: 7718262
[TBL] [Abstract][Full Text] [Related]
20. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody.
Pearson JW; Fogler WE; Volker K; Usui N; Goldenberg SK; Gruys E; Riggs CW; Komschlies K; Wiltrout RH; Tsuruo T
J Natl Cancer Inst; 1991 Oct; 83(19):1386-91. PubMed ID: 1681110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
